Endonovo Therapeutics Appoints Johns Hopkins Medical Director to its Scientific Advisory Board

Endonovo Therapeutics Inc., a commercial-stage developer of non-invasive Electroceutical therapeutic devices, has appointed Steven Levin, M.D., to its scientific advisory board. Dr. Levin will work with the Endonovo team to facilitate the introduction of SofPulse to healthcare facilities and further develop the Electroceutical devices pipeline.
 
“Dr. Levin’s vast experience with novel therapies in the anesthesiology and pain management field, as well as his strong research interest to improve clinical practice in pain management, will be valuable scientific additions to Endonovo,” said Alan Collier, CEO, Endonovo Therapeutics. “As a leader in the field of pain management, Steven will contribute valuable knowledge and expertise as we move our programs forward.”
 
Dr. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Md. Additionally, he is an assistant professor at Johns Hopkins School of Medicine, Department of Anesthesiology.
Dr. Levin is currently the co-chair of the Opioid Stewardship Clinical Community as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System. He has previously served on the medical school facility at Yale University and at University of Pittsburgh Medical Center.

“It is a great opportunity to participate in developing Endonovo’s promising fight to support pain management and healing in a natural and holistic way,” said Dr. Levin. “I look forward to helping guide Endonovo’s breakthrough treatments and fight against the opioid crisis as a member of the scientific advisory board.”
 
Dr. Levin received his undergraduate degree from University of Pennsylvania and medical degree at the University of Pittsburgh. He completed his residency and fellowship at the University of Pittsburgh Medical Center. His membership in professional and scientific societies has included the American Society of Anesthesiology, American Pain Society, American Society of Regional Anesthesia, Society in Anesthesia and International Association for the Study of Pain.
 
Collier concluded, “As we look to establish and expand a scientific board, Steven is a natural fit for us. I am looking for experienced experts that have the ability to communicate in the medical community the effectiveness and safety SofPulse as a replacement for opioids in post-surgery and care.”

Endonovo Therapeutics Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The company’s non-invasive Electroceutical therapeutic device, SofPulse, using pulsed short-wave radiofrequency at 27.12 MHz has been U.S. Food and Drug Administration-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The company’s current portfolio of pre-clinical stage Electroceuticals therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The company’s non-invasive, wearable Electroceuticals therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.